<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603391</url>
  </required_header>
  <id_info>
    <org_study_id>IRB202002547-A</org_study_id>
    <secondary_id>OCR39758</secondary_id>
    <nct_id>NCT04603391</nct_id>
  </id_info>
  <brief_title>Cannabidiol and CES1 Interactions in Healthy Subjects</brief_title>
  <official_title>An Assessment of the Drug Interaction Potential Between Oral Cannabidiol (Epidiolex®) and the CES1 Substrate Methylphenidate in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>State of Florida Consortium for Medical Marijuana Clinical Outcomes Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will assess the drug interaction potential between oral cannabidiol&#xD;
      (Epidiolex®) and the carboxylesterase 1 (CES1) substrate methylphenidate (Ritalin®) in 12&#xD;
      healthy research subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>An open-label, randomized crossover design is proposed wherein healthy volunteer subjects (n=12) would receive a single dose of immediate-release dl-methylphenidate (Ritalin®) concomitantly with orally administered CBD (Epidiolex®) solution or an equal volume of Epidiolex® placebo solution (i.e vehicle with no CBD) which have been dosed to plasma steady-state conditions.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in the geometric mean ratios (GMR) of the pharmacokinetic parameters will be compared between the two exposure conditions; i.e. methylphenidate + CBD vs methylphenidate + placebo.</measure>
    <time_frame>8 hours for each exposure condition for pharmacokinetic assessments</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Drug Interaction</condition>
  <arm_group>
    <arm_group_label>Exposure A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) CBD 750 mg (administered as 7.5 ml of Epidiolex® solution [100 mg/ml] of CBD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exposure B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) 7.5 ml of Epidiolex® placebo solution containing no CBD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>di-Methylphenidate plus Cannabidiol</intervention_name>
    <description>Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) plus CBD 750 mg (administered as 7.5 ml of Epidiolex® solution [100 mg/ml] of CBD)</description>
    <arm_group_label>Exposure A</arm_group_label>
    <other_name>Ritalin®</other_name>
    <other_name>Epidiolex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>di-Methylphenidate plus Cannabidiol Placebo solution</intervention_name>
    <description>Subjects will be administered one (1) 10 mg tablet of dl-methylphenidate (Ritalin®) 7.5 ml of Epidiolex® placebo solution containing no CBD.</description>
    <arm_group_label>Exposure B</arm_group_label>
    <other_name>Ritalin®</other_name>
    <other_name>Epidiolex®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Age: 21-45 years&#xD;
&#xD;
          -  Gender: males and females (50:50)&#xD;
&#xD;
          -  Race or ethnicity: no restrictions&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.5 to 28 kg/m2 (inclusive)&#xD;
&#xD;
          -  Satisfactory completion of the screening medical history, physical exam, and&#xD;
             laboratory evaluations.&#xD;
&#xD;
          -  Females of child-bearing potential must have a negative urine pregnancy test prior to&#xD;
             enrollment and avoid pregnancy during study participation.&#xD;
&#xD;
          -  With the exception of oral contraceptives, subjects must not be taking prescription or&#xD;
             OTC medication for the duration of study participation&#xD;
&#xD;
          -  Subjects must have no ongoing use of any botanical/nutritional supplement, vitamin, or&#xD;
             energy drink for the duration of study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of a known allergy, hypersensitivity, or adverse reaction to CBD or&#xD;
             cannabis, or sesame seed oil&#xD;
&#xD;
          -  The presence of a known allergy, hypersensitivity, or adverse reaction to&#xD;
             methylphenidate or dexmethylphenidate (Focalin®)&#xD;
&#xD;
          -  A history (within the past year) or presence of clinically significant cardiovascular,&#xD;
             cerebrovascular, renal, hepatic, gastrointestinal, pulmonary, immunological,&#xD;
             hematological, endocrine, or neurologic disease will render subjects ineligible for&#xD;
             the study.&#xD;
&#xD;
          -  The presence of any surgical or medical condition (active or chronic) that may&#xD;
             interfere with drug absorption, distribution, metabolism, or excretion including;&#xD;
&#xD;
               1. Gastric bezoar&#xD;
&#xD;
               2. Swallowing disorders&#xD;
&#xD;
               3. Strictures&#xD;
&#xD;
               4. Fistulas&#xD;
&#xD;
               5. GI obstruction&#xD;
&#xD;
               6. Severe dsyphasgia&#xD;
&#xD;
               7. Crohn's disease&#xD;
&#xD;
               8. Diverticulitis&#xD;
&#xD;
               9. A positive urine pregnancy test.&#xD;
&#xD;
              10. A positive Urine Drug Screen&#xD;
&#xD;
              11. Any concomitant prescription medication, OTC medication, herbal or other dietary&#xD;
                  supplement or vitamins during the study period.&#xD;
&#xD;
        All subjects must be medication-free from 7 Days before initiation of the first active&#xD;
        study day, through the duration of the study. This exclusion the use of vitamins, herbal&#xD;
        preparations and OTC supplements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Markowitz, Pharm.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ben Burkley</last_name>
    <phone>352-273-5283</phone>
    <email>burkley@cop.ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Markowitz, Pharm.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

